Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
Breast Cancer Research and Treatment|February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyMiguel Martin, Jan C Brase, Amparo Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialM H Kulke, P Ruszniewski, E Van Cutsem, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Plos Biology|April 30, 2024
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's diseaseAbdallah M Eteleeb, Brenna C Novotny, Carolina Soriano Tarraga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
Cancer Research Communications|March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N TrialsBenjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Critical Care Medicine|July 1, 1997
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator GroupS M Opal, C J Fisher, J F Dhainaut, et al.
Cancer Discovery|August 30, 2012
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylationStefan T Börno, Axel Fischer, Martin Kerick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Pageof 21